BIOMARKER:

NRAS Q61K

Entrez ID:

Related biomarkers:

‹

›

NRAS Q61K NRAS Q61K	Melanoma Melanoma	trametinib + dabrafenib Resistant: C3 – Early Trials
NRAS Q61K NRAS Q61K	Hepatocellular Cancer HCC	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
NRAS Q61K NRAS Q61K	Melanoma Melanoma	vemurafenib Resistant: C3 – Early Trials
NRAS Q61K NRAS Q61K	Melanoma Melanoma	HL-085 Sensitive: C3 – Early Trials
NRAS Q61K NRAS Q61K	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	selumetinib Sensitive: C3 – Early Trials
NRAS Q61K NRAS Q61K	Non Small Cell Lung Cancer NSCLC	trametinib Sensitive: C3 – Early Trials
NRAS Q61K NRAS Q61K	Melanoma Melanoma	LY3009120 Sensitive: D – Preclinical
NRAS Q61K NRAS Q61K	Melanoma Melanoma	trametinib + palbociclib Resistant: D – Preclinical
NRAS Q61K NRAS Q61K	Melanoma Melanoma	selumetinib Sensitive: D – Preclinical
NRAS Q61K NRAS Q61K	Melanoma Melanoma	trametinib Resistant: D – Preclinical
NRAS Q61K NRAS Q61K	Melanoma Melanoma	SBI-756 Sensitive: D – Preclinical
NRAS Q61K NRAS Q61K	Melanoma Melanoma	dabrafenib Resistant: D – Preclinical